Patents by Inventor Qing Ye

Qing Ye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10525077
    Abstract: The present invention provides an oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and an application thereof. The core sequence of the oligodeoxy nucleotide is TTYSGGAAWT, wherein Y is C or T; S is C or G; and W is A or T. The oligodeoxy nucleotide above further comprises an antisense strand and a modified type thereof. The oligodeoxy nucleotide according to the present invention plays a role of inhibiting the tumor growth in vitro and vivo, and is expected to be used for preparing drugs for inhibiting tumor growth, with high specificity and high inhibition ratio.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: January 7, 2020
    Assignees: JIANGSU KEYGEN BIOTECH CORP., LTD, NANJING NEW INDUSTRY INVESTMENT GROUP CO., LTD
    Inventors: Xuegen Wang, Qing Ye, Yijun Sun
  • Patent number: 10528522
    Abstract: At least one application data set stored in a data repository is obtained. The application data set is analyzed to generate at least one metadata node. The at least one metadata node is combined with at least one other related node to form a hierarchical data structure. One or more valuation algorithms are executed against the hierarchical data structure to calculate a value for the data set represented in the hierarchical data structure.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: January 7, 2020
    Assignee: EMC IP Holding Company LLC
    Inventors: Stephen Todd, Anand Singh, Sudhir Vijendra, Narayanan Krishnakumar, Qing Ye
  • Patent number: 10517466
    Abstract: The present invention discloses a capsule endoscope and a method to prevent the capsule from being covered by a residue or mucous in a patient's digestive tract. The capsule endoscope comprises an improved surface, preventing a residue or mucous to adhere onto the surface of the capsule, and in the unlikely event that a residue or a mucous is collected by the capsule the improved surface can allow an easy and successful clean before an image is taken.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: December 31, 2019
    Assignee: ANKON MEDICAL TECHNOLOGIES (SHANGHAI), LTD
    Inventors: Qing Ye, Xiaodong Duan
  • Patent number: 10483949
    Abstract: A driving circuit for driving a power switch. The driving circuit and the power switch are collaboratively defined as an equivalent circuit. The equivalent circuit includes a first equivalent capacitor corresponding to an input capacitor of the power switch, an equivalent inductor, and a second equivalent capacitor corresponding to a parasitic parameter of at least one driving switch. In the charging procedure or the discharging of the first equivalent capacitor, a change amount of charges in the first equivalent capacitor while a voltage of the input capacitor is changed from a voltage corresponding to no inductor current to a set voltage is larger than or equal to a change amount of charges in the second equivalent capacitor while the voltage of the input capacitor is changed from the voltage corresponding to no inductor current to a steady voltage.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: November 19, 2019
    Assignee: DELTA ELECTRONICS, INC.
    Inventors: Pei-Qing Hu, Jian-Hong Zeng, Hao-Yi Ye
  • Publication number: 20190329176
    Abstract: An aqueous solvent composition is provided, comprising a nucleophilic component having one or more sterically unhindered primary or secondary amine moieties, a Brønsted base component having one or more basic nitrogen moieties, a water-soluble organic solvent, and water. A biphasic composition is provided, comprising one or more carbamate compounds, one or more conjugate acids of Brønsted base, a water-soluble organic solvent, and water. A biphasic CO2 absorption process is also provided, utilizing the biphasic solvent composition.
    Type: Application
    Filed: April 3, 2019
    Publication date: October 31, 2019
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Yongqi LU, Yang Du, Qing Ye
  • Patent number: 10441600
    Abstract: The present invention provides an oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and an application thereof. The core sequences of the oligodeoxy nucleotide is TTTCSCGCS, wherein S is C or G. The oligodeoxy nucleotide above further comprises an antisense strand and a modified type thereof. The oligodeoxy nucleotide according to the present invention plays a role of inhibiting the tumor growth in vitro and vivo, and is expected to be used for preparing drugs for inhibiting tumor growth, with high specificity and high inhibition ratio.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: October 15, 2019
    Assignees: JIANGSU KEYGEN BIOTECH CORP., LTD, NANJING NEW INDUSTRY INVESTMENT GROUP CO., LTD
    Inventors: Xuegen Wang, Qing Ye, Yijun Sun
  • Patent number: 10411608
    Abstract: A converter circuit includes an inverter and a controller. The inverter is configured to receive an input voltage and to convert the input voltage into a primary-side alternating-current (AC) voltage in a first inversion mode or a second inversion mode. Each of a first switch unit and a second switch unit in the inverter includes switches. When the converter circuit works in the first inversion mode, the controller controls switches of the first switch unit and the second switch unit to cooperatively switch on and switch off periodically according to an output voltage corresponding to the primary-side AC voltage. When the converter circuit works in the second inversion mode, the controller controls the first switch unit to operate independently, in which the switches of the first switch unit switch on and switch off periodically.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: September 10, 2019
    Assignee: DELTA ELECTRONICS (SHANGHAI) CO., LTD.
    Inventors: Yi-Qing Ye, Chao Yan, Li-Ping Sun
  • Publication number: 20190185485
    Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15,016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
    Type: Application
    Filed: December 18, 2018
    Publication date: June 20, 2019
    Inventors: Alexander HIRD, Matthew BELMONTE, Wenzhan YANG, Paul SECRIST, Daniel ROBBINS, Steven KAZMIRSKI, Dedong WU, Bo PENG, Jeffrey JOHANNES, Michelle LAMB, Qing YE, Xiaolan ZHENG
  • Publication number: 20190178443
    Abstract: Method of constructing a vault of a large storage tank for liquefied natural gas by first modeling the vault with a 3-D modeling software application, then partially building the vault with a framework and a first set of covering panels fixed on the framework where the panels do not touch each other, but leave a number of gaps between them, measuring the dimensions of the actual gaps between the panels using a 3-D scanner, producing a second set of panels according to the scanned dimensional data, and finally filled the gaps between the first set of panels with the second set of panels, which are much smaller than the first set of panels, making the building process earlier and more accurate, which are difficult issues in building large tanks for liquefied natural gas.
    Type: Application
    Filed: December 13, 2017
    Publication date: June 13, 2019
    Applicants: CHINA NATIONAL OFFSHORE OIL CORP., OFFSHORE OIL ENGINEERING CO., LTD., Tianjin University
    Inventors: Zhongzhi YE, Jing LU, Xiqiang ZHANG, Juan SU, Jian SU, Qing ZHANG, Yu SUN, Fudan ZHOU, Yu WANG, Wenduo HE
  • Publication number: 20190166214
    Abstract: A method and an apparatus for pushing information are provided. The method includes: acquiring at least two browser cache files, the at least two browser cache files having identical terminal device attribute information and being from a terminal device having a target Internet protocol IP address; determining, based on an identifier set from the terminal device having the target IP address, a number of the terminal device having the target IP address, and the identifier set including at least one of: a device identifier set, an application identifier set, or a browser cache file identifier set; and determining and pushing a probability that the at least two browser cache files are from a same terminal device based on the number of the terminal device having the target IP address and a predetermined probability that one arbitrary terminal devices has the terminal device attribute information.
    Type: Application
    Filed: September 17, 2018
    Publication date: May 30, 2019
    Inventors: Canxiang ZHENG, Qiang LI, Qing YE
  • Patent number: 10251907
    Abstract: The present invention provides an oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and an application thereof. The core sequence of the oligodeoxy nucleotide is RGGGAHTTYCS, wherein R is G or A; H is A or C or T; Y is C or T; S is C or G. The oligodeoxy nucleotide above further comprises an antisense strand and a modified type thereof. The oligodeoxy nucleotide according to the present invention plays a role of inhibiting the tumor growth in vitro and vivo, and is expected to be used for preparing drugs for inhibiting tumor growth, with high specificity and high inhibition ratio.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: April 9, 2019
    Assignees: NANJING NEW INDUSTRY INVESTMENT GROUP CO., LTD, JIANGSU KEYGEN BIOTECH CORP., LTD
    Inventors: Xuegen Wang, Qing Ye, Yijun Sun
  • Patent number: 10196404
    Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: February 5, 2019
    Assignee: AstraZeneca AB
    Inventors: Alexander Hird, Matthew Belmonte, Wenzhan Yang, Paul Secrist, Daniel Robbins, Steven Kazmirski, Dedong Wu, Bo Peng, Jeffrey Johannes, Michelle Lamb, Qing Ye, Xiaolan Zheng
  • Publication number: 20190023809
    Abstract: The present disclosure provides anti-NAMPT cDNA clones and the amino acid sequences encoded by the clones. Such clones and amino acid sequences are combinable in several variations and can be used to decrease NAD synthesis in a targeted cell population.
    Type: Application
    Filed: September 6, 2016
    Publication date: January 24, 2019
    Inventors: Shui Qing Ye, Daniel P. Heruth, Li Qin Zhang
  • Publication number: 20180333497
    Abstract: Provided herein are methods for reducing clearance of nanotherapeutic agents from a subject, wherein the methods comprise administering a nutrition supplement to the subject prior to administration of the nanotherapeutic agent in the treatment of a disease. Methods for improving the bioavailability of the nanotherapeutic agent, methods of reducing the toxicity of the nanotherapeutic agent, and kits comprising the nutrition supplement and nanotherapeutic agent are also provided.
    Type: Application
    Filed: February 18, 2016
    Publication date: November 22, 2018
    Inventors: Chien Ho, Li Liu, Qing Ye
  • Publication number: 20180184731
    Abstract: A leg-protecting apparatus is arranged in close contact with a body surface of a wearer to cover a thigh, a knee, and a calf of the wearer, including a biomechanically protecting strap (A) arranged to correspond with structural locations and paths of tendons and ligaments of the knee and muscles proximal thereto during an exercise process. The strap comprises a cruciate ligament protecting strap (A-1), a patellar tendon protecting strap (A-2), a thigh muscle group protecting strap (A-3), and a calf muscle group protecting strap (A-4). Elastic moduli of the cruciate ligament protecting strap (A-1) and the patellar tendon protecting strap (A-2) has a step-change upon a change in a fabric tensile ratio caused by the knee bending of the wearer, wherein the step-change occurs after an initial low tensile modulus stage, during a tensile sudden-change stage, and before a high tensile modulus stage transitioning between the stages as knee angle decreases.
    Type: Application
    Filed: June 17, 2015
    Publication date: July 5, 2018
    Applicant: The Hong Kong Research Institute of Textiles and Apparel Limited
    Inventors: Yi LI, Yinglei LIN, Shu SUN, Xiao HAN, Jinyun ZHOU, Xuyong CAO, Yueping GUO, Jiao JIAO, Ru LV, Qing YE
  • Publication number: 20180155362
    Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
    Type: Application
    Filed: October 23, 2017
    Publication date: June 7, 2018
    Applicant: AstraZeneca AB
    Inventors: Alexander HIRD, Matthew BELMONTE, Wenzhan YANG, Paul SECRIST, Daniel ROBBINS, Steven KAZMIRSKI, Dedong WU, Bo PENG, Jeffrey JOHANNES, Michelle LAMB, Qing YE, Xiaolan ZHENG
  • Publication number: 20180140627
    Abstract: The present invention provides an oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and an application thereof. The core sequences of the oligodeoxy nucleotide is TTTCSCGCS, wherein S is C or G. The oligodeoxy nucleotide above further comprises an antisense strand and a modified type thereof. The oligodeoxy nucleotide according to the present invention plays a role of inhibiting the tumor growth in vitro and vivo, and is expected to be used for preparing drugs for inhibiting tumor growth, with high specificity and high inhibition ratio.
    Type: Application
    Filed: June 25, 2015
    Publication date: May 24, 2018
    Inventors: Xuegen Wang, Qing Ye, Yijun Sun
  • Publication number: 20180142238
    Abstract: The present invention provides an oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and an application thereof. The core sequence of the oligodeoxy nucleotide is TTYSGGAAWT, wherein Y is C or T; S is C or G; and W is A or T. The oligodeoxy nucleotide above further comprises an antisense strand and a modified type thereof. The oligodeoxy nucleotide according to the present invention plays a role of inhibiting the tumor growth in vitro and vivo, and is expected to be used for preparing drugs for inhibiting tumor growth, with high specificity and high inhibition ratio.
    Type: Application
    Filed: June 25, 2015
    Publication date: May 24, 2018
    Inventors: Xuegen Wang, Qing Ye, Yijun Sun
  • Publication number: 20180133154
    Abstract: A preparation method of a Decoy nucleic acid cationic liposome carrier including: (1) mixing dioleoyl phosphoethanolamine and (2,3-dioleoyl-propyl)-trimethylamine in a mass ratio of 4:1 to 1:4, and adding an organic solvent to obtain a mixed solution through dissolution; (2) completely evaporating the organic solvent in the mixed solution obtained in step (1), dissolving the remaining solid fraction by using an HEPES buffer solution, firstly hydrating the solution for 30 to 60 min, and then ultrasonically processing the solution for 30 to 60 min; (3) filtering the mixed system obtained after processing in the step (2) by a membrane of 0.4 to 0.8 ?m, then filtering the mixed system by a membrane of 0.03 to 0.2 ?m, and preparing uniformly to distributed blank liposome with small grain size; and (4) mixing the blank liposome with protamine and Decoy nucleic acid according to a mass ratio of (50 to 120):(10 to 20):1, and incubating for 12 to 24 h at the temperature of 2° C. to 8° C.
    Type: Application
    Filed: July 8, 2015
    Publication date: May 17, 2018
    Inventors: Yang Xiao, Jinlong Cui, Zhengrong Li, Qing Ye, Lingyun He, Xuegen Wang
  • Publication number: 20180135047
    Abstract: The present invention provides an oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and an application thereof. The core sequence of the oligodeoxy nucleotide is RGGGAHTTYCS, wherein R is G or A; H is A or C or T; Y is C or T; S is C or G. The oligodeoxy nucleotide above further comprises an antisense strand and a modified type thereof. The oligodeoxy nucleotide according to the present invention plays a role of inhibiting the tumor growth in vitro and vivo, and is expected to be used for preparing drugs for inhibiting tumor growth, with high specificity and high inhibition ratio.
    Type: Application
    Filed: June 25, 2015
    Publication date: May 17, 2018
    Inventors: Xuegen Wang, Qing Ye, Yijun Sun